Mkt Cap$2.21T-1.40%
24h Vol$107.57B
BTC Dom56.0%
ETH Dom9.0%
F&G9Extreme Fear
BTC$61,697.00-1.35% ETH$1,638.89-2.10% USDT$0.9992-0.03% BNB$589.43-1.27% USDC$0.9998+0.02% XRP$1.12-3.48% SOL$64.29-2.63% TRX$0.3225-0.12% FIGR_HELOC$1.03+0.55% DOGE$0.084-1.90% HYPE$56.20-9.36% USDS$0.9997-0.01% LEO$9.46+0.48% RAIN$0.0132+1.83% ZEC$426.29-9.11% CC$0.1666+1.04% BTC$61,697.00-1.35% ETH$1,638.89-2.10% USDT$0.9992-0.03% BNB$589.43-1.27% USDC$0.9998+0.02% XRP$1.12-3.48% SOL$64.29-2.63% TRX$0.3225-0.12% FIGR_HELOC$1.03+0.55% DOGE$0.084-1.90% HYPE$56.20-9.36% USDS$0.9997-0.01% LEO$9.46+0.48% RAIN$0.0132+1.83% ZEC$426.29-9.11% CC$0.1666+1.04%
News

VNDA

Total Stories
2
Section
VNDA
Vanda (VNDA) Stock Skyrockets on FDA Approval for Bipolar, Schizophrenia Drug
Market Analysis

Vanda (VNDA) Stock Skyrockets on FDA Approval for Bipolar, Schizophrenia Drug

Vanda stock jumped more than 40% in premarket trading after the FDA approved its new drug BYSANTI for Bipolar I disorder and schizophrenia.

Tim FriesFeb 23, 20263 min read